Mateja Črček

Mateja Črček

Auto-generated profile, based on publicly available information

Mateja Črček

University of Ljubljana, Faculty of Pharmacy , Department of Biopharmacy and Pharmacokinetics , Ljubljana Slovenia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
MČMateja Črček
Mateja Črček
IGIztok Grabnar
Iztok Grabnar
JZJurij Zdovc
Jurij Zdovc
Stefan GrosekStefan Grosek
Stefan Grosek
MKMojca Kerec Kos
Mojca Kerec Kos
The aim of this study was to externally validate the predictive performance of published population pharmacokinetic models of gentamicin in all paediatric age groups, from preterm newborns to adolescents. We first selected published population pharmacokinetic models of gentamicin developed in the paediatric population with a wide age range. The parameters of the literature models were then re-estimated using the PRIOR subroutine in NONMEM ® . The predictive ability of the literature and the tweaked models was evaluated. Retrospectively collected data from a routine clinical practice (512 concentrations from 308 patients) were used for validation. The models with covariates characterising developmental changes in clearance and volume of distribution had better predictive performance, which improved further after re-estimation. The tweaked model by Wang 2019 performed best, with suitable accuracy and precision across the complete paediatric population. For patients treated in the intensive care unit, a lower proportion of patients would be expected to reach the target trough concentration at standard dosing. The selected model could be used for model-informed precision dosing in clinical settings where the entire paediatric population is treated. However, for use in clinical practice, the next step should include additional analysis of the impact of intensive care treatment on gentamicin pharmacokinetics, followed by prospective validation.